SBFM Sunshine Biopharma Inc.
Financings ·
A preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees.
Sunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent.
The reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent.
The company says 2025 revenue rose 4.1% and its net loss was $5.98 million, which it attributes partly to a $1.75 million impairment charge, and it expects cost cuts of $2 million to $3 million in 2026.
Sunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116.
The company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date.
The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.
Sunshine Biopharma Inc. is a pharmaceutical company offering and researching medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its Canadian subsidiary Nora Pharma Inc., it has 71 generic prescription drugs on the market in Canada. Nora Pharma obtains rights through in-licensing and supply agreements, cross-licensing or distribution agreements, and files with Health Canada where needed. Its other subsidiary, Sunshine Biopharma Canada Inc., develops and sells OTC supplements. The company's proprietary drug development program includes K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and SBFM-PL4, a protease inhibitor for SARS Coronavirus infections. Both are in animal testing. The company has 22 additional drugs in its pipeline, including 12 it anticipates launching during the remainder of 2026. It cites the Canadian $10.4 billion a year generic drugs market.
| Product or program | What it is | Stage |
|---|---|---|
| Generic prescription drugs (Nora Pharma) | Generic medicines sold in Canada under its own or partners' labels | 71 on the market in Canada |
| K1.1 mRNA | LNP encapsulated mRNA targeted for liver cancer | Animal Testing |
| SBFM-PL4 | Protease inhibitor for SARS Coronavirus infections | Animal Testing |
| OTC supplements (Sunshine Biopharma Canada) | Over-the-counter supplements developed and sold by the Canadian subsidiary | Sold |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $36.3 million | $34.9 million |
| Research and development | $604,308 | $933,902 |
| Net income (loss) | -$6.0 million | -$5.1 million |
| Cash from operations | -$5.3 million | -$12.5 million |
| Cash and equivalents | $9.1 million | $9.7 million |
Our latest story on this, dated Oct 2, 2026: "Sunshine Biopharma files for $7,000,000 unit offering, later priced at $0.55 per unit". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2025: "Sunshine Biopharma files NT 10-K late-filing notice for 2024 annual report". The story links the filing or release it is based on. Read the story.
Sunshine Biopharma Inc. trades under the ticker SBFM on NASDAQ.
Sunshine Biopharma Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Sunshine Biopharma Inc. is 1402328. Its filings are on SEC EDGAR.
3,877,337 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Sunshine Biopharma Inc. under United States.
Our directory classifies Sunshine Biopharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sunshine Biopharma Inc. is US8677818093.
aibio.space lists Sunshine Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as CO.
Sunshine Biopharma Inc. is a pharmaceutical company offering and researching medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its Canadian subsidiary Nora Pharma Inc., it has 71 generic prescription drugs on the market in Canada.
Generic prescription drugs (Nora Pharma): Generic medicines sold in Canada under its own or partners' labels Stage: 71 on the market in Canada.
K1.1 mRNA: LNP encapsulated mRNA targeted for liver cancer Stage: Animal Testing.
$36.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form S-1. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio